Immuneering (IMRX) Total Non-Current Liabilities (2022)
Immuneering (IMRX) recorded quarterly Total Non-Current Liabilities of $8.4 million in Q2 2022, up 0.76% quarter-over-quarter from $8.4 million in Q1 2022.
Immuneering (IMRX) Total Non-Current Liabilities (2022) Analysis & Trends
Immuneering's Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $8.4 million for Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 64.76 Mn |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 8.45 Mn |
| Mar 31, 2022 | 8.38 Mn |